MET and renal carcinoma: High MET expression could be associated with poor prognosis in renal cancer, and an in vivo study showed MET phosphorylation enhanced by chronic sunitinib exposure could lead to enhanced migration of affected cells by activating signaling pathways, causing epithelial-mesenchymal transition [32,33].